Phase 3 study of buntanetap: potential cognitive effects in patients with Parkinson's disease dementia

Buntanetap is an orally available small RNA targeting molecule that inhibits the translation of multiple neurotoxic aggregating proteins, including amyloid precursor protein (APP) and Tau. It has been evaluated in over 1200 participants, including healthy volunteers, patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD), and has shown a favorable safety and tolerability profile. We evaluated the safety and efficacy of buntanetap in treating early PD patients with MMSE ≥ 20 in this 6-month randomized double-blind dose-ranging study. A total of 523 early PD patients were enrolled In the US and in 6 different countries in the European Union (Germany, Spain, Italy, Poland, Hungary) across a total of 67 sites (42 in the United States and 25 in the European Union). Patients were given either 10, 20 mg buntanetap or placebo. Buntanetap had a favorable safety profile. The study did not meet its primary endpoints (MDS-UPDRS Part II). However, in a post-hoc analysis, buntanetap improved patients’ cognition. In amyloid-positive PD patients with mild cognitive impairment and mild dementia, buntanetap not only demonstrated nominally statistically significant dose-dependent cognitive benefits but also showed potential improvement in all MDS-UPDRS and other scales tested. These findings were supported by biomarker evidence of target engagement. Further evaluations of buntanetap in this patient population are warranted.

Authors

Institutions

Publication Details

Journal
npj Dementia
Published
2026-11-19
DOI
https://doi.org/10.1038/s44400-026-00148-x
Primary Topic
Parkinson's Disease Mechanisms and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Phase 3 study of buntanetap: potential cognitive effects in patients with Parkinson's disease dementia

Jason L. Aldred, Aaron L. Ellenbogen, Maria Francesca De Pandis, Cheng Fang et al.
npj Dementia
Parkinson's Disease Mechanisms and Treatments
article

Phase 3 study of buntanetap: potential cognitive effects in patients with Parkinson's disease dementia

Jason L. Aldred, Aaron L. Ellenbogen, Maria Francesca De Pandis, Cheng Fang, Martin Rhys Farlow, Robert A. Hauser, Daniel T. Laskowitz, Melissa Gaines, Rekha Gandhi, Maria L. Maccecchini, Michael Chen, Fabrizio Stocchi, David Feng
article en

Abstract

Buntanetap is an orally available small RNA targeting molecule that inhibits the translation of multiple neurotoxic aggregating proteins, including amyloid precursor protein (APP) and Tau. It has been evaluated in over 1200 participants, including healthy volunteers, patients with Alzheimer’s disease (AD) and Parkinson’s disease (PD), and has shown a favorable safety and tolerability profile. We evaluated the safety and efficacy of buntanetap in treating early PD patients with MMSE ≥ 20 in this 6-month randomized double-blind dose-ranging study. A total of 523 early PD patients were enrolled In the US and in 6 different countries in the European Union (Germany, Spain, Italy, Poland, Hungary) across a total of 67 sites (42 in the United States and 25 in the European Union). Patients were given either 10, 20 mg buntanetap or placebo. Buntanetap had a favorable safety profile. The study did not meet its primary endpoints (MDS-UPDRS Part II). However, in a post-hoc analysis, buntanetap improved patients’ cognition. In amyloid-positive PD patients with mild cognitive impairment and mild dementia, buntanetap not only demonstrated nominally statistically significant dose-dependent cognitive benefits but also showed potential improvement in all MDS-UPDRS and other scales tested. These findings were supported by biomarker evidence of target engagement. Further evaluations of buntanetap in this patient population are warranted.

npj DementiaVol. 2(1)
Duke University (US), University of South Florida (US), Quest Research Institute (US), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), Indiana University Indianapolis (US), Duke Clinical Research Institute (US)
Parkinson's Disease Mechanisms and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon